Alexion Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:ALXN)

Analyst Price Target for ALXN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$152.96

▼ -3.03% Downside Potential

This price target is based on 27 analysts offering 12 month price targets for Alexion Pharmaceuticals in the last 3 months. The average price target is $152.96, with a high forecast of $200.00 and a low forecast of $73.00. The average price target represents a -3.03% upside from the last price of $157.74.

Hold

The current consensus among 27 contributing investment analysts is to hold stock in Alexion Pharmaceuticals. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

7/30/2019

0 strong buy ratings
6 buy ratings
12 hold ratings
0 sell ratings

Ratings as of

10/28/2019

0 strong buy ratings
8 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

1/26/2020

0 strong buy ratings
10 buy ratings
12 hold ratings
0 sell ratings

Ratings as of

4/25/2020

1 strong buy ratings
11 buy ratings
12 hold ratings
0 sell ratings

Ratings as of

7/24/2020

1 strong buy ratings
9 buy ratings
12 hold ratings
0 sell ratings

Ratings as of

10/22/2020

1 strong buy ratings
10 buy ratings
16 hold ratings
0 sell ratings

Ratings as of

12/21/2020

1 strong buy ratings
10 buy ratings
16 hold ratings
0 sell ratings

Ratings as of

1/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/8/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		Low	i
12/16/2020	Truist	Downgrade	Buy ➝ Hold	$155.00 ➝ $175.00	Medium	i
12/15/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$175.00	Low	i
12/15/2020	Roth Capital	Boost Price Target		$50.00 ➝ $73.00	Low	i
12/15/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Reiterated Rating	Buy ➝ Neutral	$175.00	Low	i
12/14/2020	SVB Leerink	Boost Price Target	Outperform	$159.00 ➝ $200.00	High	i
12/14/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$140.00 ➝ $175.00	High	i
12/14/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$175.00	High	i
12/14/2020	Royal Bank of Canada	Boost Price Target	Outperform	$139.00 ➝ $175.00	High	i
12/14/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$152.00 ➝ $175.00	High	i
12/14/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$147.00 ➝ $194.00	High	i
11/19/2020	Sanford C. Bernstein	Initiated Coverage	Market Perform	$148.00	Low	i
11/5/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target		$145.00 ➝ $157.00	Low	i
11/5/2020	Smith Barney Citigroup	Boost Price Target		$145.00 ➝ $157.00	Low	i
11/5/2020	Royal Bank of Canada	Reiterated Rating	Buy		Medium	i
10/30/2020	Svb Leerink	Lower Price Target	Overweight ➝ Outperform	$163.00 ➝ $159.00	Low	i
10/30/2020	SVB Leerink	Boost Price Target	Outperform	$159.00 ➝ $163.00	Medium	i
10/30/2020	Morgan Stanley	Lower Price Target	Equal Weight	$121.00 ➝ $119.00	Medium	i
10/29/2020	Piper Sandler	Boost Price Target	Overweight	$175.00 ➝ $179.00	Medium	i
10/28/2020	UBS Group	Initiated Coverage	Neutral	$133.00	High	i
10/13/2020	Morgan Stanley	Boost Price Target	Equal Weight	$120.00 ➝ $121.00	Low	i
10/7/2020	Royal Bank of Canada	Boost Price Target	Outperform	$136.00 ➝ $139.00	High	i
10/7/2020	William Blair	Reiterated Rating	Hold		High	i Rating by R. Prasad at William Blair
10/6/2020	Wedbush	Reiterated Rating	Outperform	$156.00	Low	i
9/1/2020	Stifel Nicolaus	Lower Price Target	Hold	$120.00 ➝ $117.00	Low	i
7/31/2020	Raymond James	Lower Price Target	Outperform	$156.00 ➝ $151.00	Low	i
7/31/2020	SunTrust Banks	Boost Price Target	Outperform ➝ Buy	$135.00 ➝ $155.00	Medium	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
7/31/2020	SVB Leerink	Boost Price Target	Outperform	$159.00 ➝ $163.00	Medium	i
7/30/2020	William Blair	Downgrade	Outperform ➝ Market Perform		High	i Rating by Raju Prasad at William Blair
7/30/2020	Oppenheimer	Reiterated Rating	Hold		Medium	i
6/1/2020	Wedbush	Boost Price Target	Outperform	$120.00 ➝ $138.00	Low	i
6/1/2020	Credit Suisse Group	Boost Price Target	Outperform	$142.00 ➝ $147.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
5/29/2020	SVB Leerink	Boost Price Target	Outperform	$150.00 ➝ $159.00	High	i
5/26/2020	Credit Suisse Group	Initiated Coverage	Buy	$142.00	High	i Rating by Martin Auster at Credit Suisse Group AG
5/8/2020	SunTrust Banks	Lower Price Target	Buy	$141.00 ➝ $135.00	Low	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/7/2020	BMO Capital Markets	Lower Price Target	Outperform	$147.00 ➝ $142.00	Low	i
5/7/2020	SVB Leerink	Lower Price Target	Outperform	$156.00 ➝ $150.00	Low	i
5/7/2020	Raymond James	Lower Price Target	Outperform	$159.00 ➝ $156.00	Low	i
5/7/2020	Morgan Stanley	Boost Price Target	Equal Weight	$116.00 ➝ $120.00	Low	i Rating by Matthew Harrison at Morgan Stanley
5/6/2020	Cfra	Lower Price Target	Strong-Buy	$165.00 ➝ $159.00	Medium	i
5/6/2020	Nomura	Reiterated Rating	Buy	$133.00	Medium	i
5/5/2020	William Blair	Downgrade	Outperform ➝ Market Perform		Medium	i Rating by Raju Prasad at William Blair
4/27/2020	Cantor Fitzgerald	Initiated Coverage	Neutral	$121.00	High	i Rating by E. Merle at Cantor Fitzgerald
4/20/2020	UBS Group	Reiterated Rating	Reduce		High	i
4/17/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$168.00 ➝ $163.00	High	i
4/15/2020	Morgan Stanley	Lower Price Target	Equal Weight	$127.00 ➝ $116.00	Low	i Rating by Matthew Harrison at Morgan Stanley
3/17/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High	i
3/12/2020	Wolfe Research	Initiated Coverage	Outperform	$140.00	High	i
3/5/2020	Bank of America	Downgrade	Buy ➝ Neutral	$130.00 ➝ $110.00	Low	i
2/25/2020	SunTrust Banks	Reiterated Rating	Buy	$141.00	Medium	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
2/3/2020	Nomura Securities	Lower Price Target	Buy	$165.00 ➝ $133.00	Low	i
1/31/2020	Robert W. Baird	Lower Price Target	Outperform	$165.00 ➝ $140.00	High	i Rating by Michael Ulz at Robert W. Baird
1/31/2020	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Positive	$135.00	Medium	i Rating by Kennen MacKay at Royal Bank of Canada
1/31/2020	Raymond James	Lower Price Target	Outperform	$162.00 ➝ $159.00	Medium	i Rating by Steven Seedhouse at Raymond James
1/31/2020	SunTrust Banks	Boost Price Target	Buy	$141.00	High	i
1/30/2020	Cowen	Reiterated Rating	Buy	$165.00	High	i Rating by Phil Nadeau at Cowen Inc
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i
1/17/2020	Morgan Stanley	Boost Price Target	Equal Weight	$128.00 ➝ $131.00	Low	i Rating by Matthew Harrison at Morgan Stanley
1/15/2020	Raymond James	Boost Price Target	Outperform	$162.00	Low	i Rating by Steven Seedhouse at Raymond James
1/14/2020	William Blair	Reiterated Rating	Buy		Medium	i Rating by Raju Prasad at William Blair
1/13/2020	Wedbush	Reiterated Rating	Outperform		High	i
12/17/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$170.00 ➝ $128.00	Low	i Rating by Matthew Harrison at Morgan Stanley
12/6/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by R. Prasad at William Blair
11/17/2019	Evercore ISI	Reiterated Rating	Buy	$145.00	Low	i
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$125.00	Low	i
10/24/2019	Oppenheimer	Lower Price Target		$165.00 ➝ $150.00	Low	i
10/17/2019	Bank of America	Initiated Coverage	Buy		Low	i
10/16/2019	Cowen	Reiterated Rating	Buy	$165.00	Low	i
10/11/2019	Morgan Stanley	Lower Price Target	Overweight	$177.00 ➝ $170.00	Low	i Rating by Matthew Harrison at Morgan Stanley
9/26/2019	William Blair	Initiated Coverage	Outperform ➝ Outperform	$146.00	High	i Rating by R. Prasad at William Blair
9/18/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low	i Rating by Kennen MacKay at Royal Bank of Canada
9/12/2019	BMO Capital Markets	Initiated Coverage	Outperform	$149.00	Low	i
9/6/2019	Piper Jaffray Companies	Set Price Target	Buy	$180.00	Low	i Rating by Christopher Raymond at Piper Jaffray Companies
9/6/2019	Credit Suisse Group	Lower Price Target	Outperform	$154.00 ➝ $146.00	High	i
9/3/2019	SVB Leerink	Set Price Target	Buy	$157.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
8/30/2019	Piper Jaffray Companies	Set Price Target	Buy	$180.00	Low	i Rating by Christopher Raymond at Piper Jaffray Companies
8/30/2019	Citigroup	Set Price Target	Buy	$150.00	Low	i Rating by Mohit Bansal at Citigroup Inc.
8/30/2019	Stifel Nicolaus	Reiterated Rating	Hold		Low	i Rating by Paul Matteis at Stifel Nicolaus
8/30/2019	Raymond James	Set Price Target	Buy	$168.00	Low	i Rating by Steven Seedhouse at Raymond James
8/30/2019	Robert W. Baird	Set Price Target	Buy	$165.00	Low	i Rating by Michael Ulz at Robert W. Baird
8/22/2019	Piper Jaffray Companies	Reiterated Rating	Buy		Low	i Rating by Christopher Raymond at Piper Jaffray Companies
8/21/2019	Morgan Stanley	Set Price Target	Buy	$177.00	N/A	i Rating by Matthew Harrison at Morgan Stanley
7/31/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$172.00	Low	i
7/25/2019	Raymond James	Boost Price Target	Outperform	$164.00 ➝ $168.00	High	i Rating by Steven Seedhouse at Raymond James
5/23/2019	Citigroup	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $165.00	Low	i
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$142.00	Low	i
5/22/2019	Wedbush	Initiated Coverage	Outperform ➝ Outperform	$173.00	Medium	i Rating by L. Chico at Wedbush
4/26/2019	Raymond James	Boost Price Target	Outperform ➝ Outperform	$161.00 ➝ $164.00	Low	i Rating by Steven Seedhouse at Raymond James
4/10/2019	Raymond James	Initiated Coverage	Outperform	$161.00	Medium	i Rating by Laura Chico at Raymond James
3/27/2019	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$165.00 ➝ $186.00	Low	i
3/21/2019	Guggenheim	Reiterated Rating	Neutral ➝ Neutral	$135.00	High	i Rating by Yatin Suneja at Guggenheim
3/13/2019	Cowen	Reiterated Rating	Buy	$165.00	Low	i
2/22/2019	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$135.00	Medium	i
2/12/2019	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$165.00 ➝ $175.00	High	i
1/22/2019	Credit Suisse Group	Reiterated Rating	Buy	$156.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
12/30/2018	Raymond James	Reiterated Rating	Buy		Low	i Rating by Laura Chico at Raymond James
12/30/2018	Credit Suisse Group	Set Price Target	Buy	$156.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
12/21/2018	Credit Suisse Group	Reiterated Rating	Buy	$156.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
12/21/2018	Raymond James	Reiterated Rating	Buy		High	i Rating by Laura Chico at Raymond James
11/26/2018	Oppenheimer	Set Price Target	Buy	$165.00	Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/14/2018	Oppenheimer	Set Price Target	Buy	$165.00	Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/13/2018	Credit Suisse Group	Set Price Target	Buy	$156.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
10/31/2018	Credit Suisse Group	Set Price Target	Buy	$156.00	High	i Rating by Martin Auster at Credit Suisse Group AG
10/25/2018	Citigroup	Lower Price Target	Buy	$195.00 ➝ $190.00	Medium	i
10/24/2018	SVB Leerink	Set Price Target	Buy	$181.00	High	i Rating by Geoff Porges at SVB Leerink LLC
10/15/2018	Credit Suisse Group	Set Price Target	Buy	$156.00	High	i Rating by Martin Auster at Credit Suisse Group AG
10/11/2018	Morgan Stanley	Boost Price Target	Overweight	$157.00 ➝ $165.00	Low	i
9/28/2018	Barclays	Boost Price Target	Positive ➝ Overweight	$175.00	Low	i
9/25/2018	Credit Suisse Group	Set Price Target	Buy	$156.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
9/25/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$130.00 ➝ $136.00	Low	i
9/25/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $195.00	Low	i
9/24/2018	Robert W. Baird	Set Price Target	Buy	$165.00	Medium	i Rating by Michael Ulz at Robert W. Baird
8/7/2018	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$154.00 ➝ $130.00	Low	i
7/27/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$150.00 ➝ $157.00	High	i
7/27/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$184.00 ➝ $188.00	High	i
7/27/2018	Jefferies Financial Group	Reiterated Rating	Hold	$123.00	High	i
7/26/2018	Evercore ISI	Reiterated Rating	Outperform	$158.00	Medium	i
6/5/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$149.00 ➝ $154.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
4/30/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$170.00 ➝ $173.00	Medium	i
4/27/2018	Credit Suisse Group	Set Price Target	Buy	$149.00	Medium	i Rating by Alethia Young at Credit Suisse Group AG
4/27/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$151.00 ➝ $155.00	Low	i
4/23/2018	Raymond James	Reiterated Rating	Buy		Low	i Rating by Laura Chico at Raymond James
4/12/2018	Nomura Securities	Boost Price Target	Buy	$165.00	Low	i
3/16/2018	Credit Suisse Group	Reiterated Rating	Outperform ➝ Outperform	$147.00 ➝ $149.00	High	i
3/15/2018	Nomura Securities	Boost Price Target	Buy ➝ Buy	$148.00 ➝ $156.00	Low	i
3/15/2018	Robert W. Baird	Set Price Target	Buy	$160.00	Low	i Rating by Michael Ulz at Robert W. Baird
3/15/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$161.00	High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
3/9/2018	Cowen	Reiterated Rating	Buy	$163.00	Low	i
2/12/2018	SunTrust Banks	Set Price Target	Buy	$172.00	Medium	i Rating by Yatin Suneja at SunTrust Banks, Inc.
2/9/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$177.00 ➝ $180.00	Low	i
2/9/2018	Stifel Nicolaus	Reiterated Rating	Buy	$151.00	Medium	i
2/9/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$148.00 ➝ $151.00	Low	i
2/9/2018	SVB Leerink	Lower Price Target	Outperform ➝ Outperform	$166.00 ➝ $153.00	Low	i
2/9/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy ➝ Buy	$163.00 ➝ $161.00	Low	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
2/9/2018	Citigroup	Lower Price Target	Buy ➝ Buy	$173.00 ➝ $170.00	Low	i
2/5/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform		High	i
1/18/2018	Credit Suisse Group	Reiterated Rating	Outperform ➝ Outperform	$147.00	Medium	i
1/4/2018	Raymond James	Reiterated Rating	Strong-Buy ➝ Outperform	$178.00 ➝ $130.00	Medium	i
1/4/2018	UBS Group	Downgrade	Strong-Buy ➝ Outperform		Medium	i
12/18/2017	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$150.00	Medium	i
12/12/2017	Credit Suisse Group	Reiterated Rating	Buy	$166.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
12/6/2017	SVB Leerink	Reiterated Rating	Buy	$169.00	Low	i
10/24/2017	Royal Bank of Canada	Boost Price Target		$166.00	N/A	i
10/24/2017	Stifel Nicolaus	Lower Price Target	Buy	$165.00 ➝ $159.00	N/A	i
10/23/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$170.00	N/A	i
9/25/2017	SVB Leerink	Reiterated Rating	Buy	$182.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$161.00	Medium	i Rating by Simos Simeonidis at Royal Bank of Canada
9/13/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy ➝ Buy	$153.00 ➝ $158.00	Low	i
9/13/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$170.00 ➝ $182.00	Medium	i Rating by Geoff Porges at SVB Leerink LLC
9/13/2017	SunTrust Banks	Reiterated Rating	Buy	$170.00 ➝ $180.00	Medium	i
9/13/2017	BMO Capital Markets	Reiterated Rating	Outperform	$168.00 ➝ $173.00	Medium	i
9/5/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$163.00 ➝ $175.00	Medium	i Rating by Anupam Rama at JPMorgan Chase & Co.
8/16/2017	Evercore ISI	Initiated Coverage	In ➝ In-Line	$137.00	Medium	i
7/28/2017	BMO Capital Markets	Reiterated Rating	Outperform	$159.00 ➝ $168.00	Low	i
7/28/2017	SVB Leerink	Boost Price Target	Outperform	$136.00 ➝ $170.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
7/28/2017	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$175.00	High	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/28/2017	Morgan Stanley	Reiterated Rating	Overweight	$141.00 ➝ $153.00	High	i
7/14/2017	SunTrust Banks	Reiterated Rating	Buy	$165.00	Low	i
7/3/2017	Cowen	Reiterated Rating	Outperform	$122.00	High	i
6/26/2017	UBS Group	Reiterated Rating	Buy	$140.00 ➝ $142.00	N/A	i
6/26/2017	Robert W. Baird	Reiterated Rating	Neutral	$145.00	Medium	i Rating by Michael Ulz at Robert W. Baird
6/22/2017	SVB Leerink	Reiterated Rating	Outperform		Low	i Rating by Geoff Porges at SVB Leerink LLC
6/14/2017	Oppenheimer	Reiterated Rating	Hold		Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/14/2017	Credit Suisse Group	Set Price Target	Buy	$164.00	Medium	i Rating by Alethia Young at Credit Suisse Group AG
6/14/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low	i Rating by Anupam Rama at JPMorgan Chase & Co.
6/14/2017	UBS Group	Reiterated Rating	Buy	$108.00	N/A	i
6/14/2017	Morgan Stanley	Reiterated Rating	Overweight	$138.00	High	i
6/9/2017	The Goldman Sachs Group	Reiterated Rating	Buy	$142.00	Low	i
6/8/2017	Jefferies Financial Group	Set Price Target	Hold	$120.00	Medium	i Rating by Eun Yang at Jefferies Financial Group Inc.
5/31/2017	UBS Group	Reiterated Rating	Buy	$143.00 ➝ $140.00	N/A	i
5/25/2017	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$101.08 ➝ $138.00	High	i Rating by Matthew Harrison at Morgan Stanley
5/25/2017	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$160.00 ➝ $153.00	High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
5/24/2017	The Goldman Sachs Group	Reiterated Rating	Buy	$158.00	High	i
5/24/2017	BMO Capital Markets	Reiterated Rating	Outperform	$158.00	High	i
5/24/2017	Stifel Nicolaus	Reiterated Rating	Buy	$157.00	High	i
5/24/2017	Barclays	Reiterated Rating	Overweight	$155.00	High	i
5/23/2017	Oppenheimer	Reiterated Rating	Hold		Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/23/2017	SVB Leerink	Reiterated Rating	Buy		Medium	i Rating by Geoff Porges at SVB Leerink LLC
5/23/2017	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		High	i Rating by Anupam Rama at JPMorgan Chase & Co.
5/9/2017	Raymond James	Reiterated Rating	Strong-Buy	$176.00	Low	i
5/9/2017	Barclays	Reiterated Rating	Overweight	$155.00	Low	i
5/1/2017	BMO Capital Markets	Reiterated Rating	Outperform	$158.00	High	i
4/28/2017	Cowen	Reiterated Rating	Outperform	$180.00	Medium	i
3/30/2017	Nomura Instinet	Reiterated Rating	Buy	$148.00	Low	i
3/29/2017	UBS Group	Initiated Coverage	Buy ➝ Buy	$138.00	N/A	i
3/27/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$177.00	Low	i
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		Low	i Rating by Geoff Porges at SVB Leerink LLC
3/13/2017	SVB Leerink	Set Price Target	Buy	$208.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$148.00	N/A	i
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A	i
2/19/2017	BMO Capital Markets	Reiterated Rating	Outperform	$166.00 ➝ $158.00	N/A	i
2/17/2017	Royal Bank of Canada	Lower Price Target	Outperform	$187.00 ➝ $177.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
2/17/2017	Credit Suisse Group	Reiterated Rating	Buy	$160.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
2/16/2017	Oppenheimer	Reiterated Rating	Hold		N/A	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/16/2017	Cowen	Reiterated Rating	Buy		N/A	i
2/8/2017	Oppenheimer	Initiated Coverage	Hold		N/A	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/7/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$170.00	N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
1/21/2017	Royal Bank of Canada	Set Price Target	Buy	$187.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
1/12/2017	BMO Capital Markets	Reiterated Rating	Outperform		N/A	i
1/9/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$187.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
1/7/2017	Robert W. Baird	Reiterated Rating	Neutral	$145.00	N/A	i Rating by Michael Ulz at Robert W. Baird
1/6/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$176.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
1/5/2017	Robert W. Baird	Upgrade	Hold		N/A	i Rating by Michael Ulz at Robert W. Baird
12/25/2016	Oppenheimer	Reiterated Rating	Hold		N/A	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
12/25/2016	SVB Leerink	Set Price Target	Buy	$211.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
12/25/2016	Jefferies Financial Group	Set Price Target	Hold	$120.00	N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
12/23/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$164.00 ➝ $160.00	N/A	i
12/23/2016	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by Geoff Porges at SVB Leerink LLC
12/23/2016	BMO Capital Markets	Reiterated Rating	Outperform	$171.00	N/A	i
12/23/2016	Robert W. Baird	Reiterated Rating	Neutral	$145.00	N/A	i
12/23/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$176.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
12/22/2016	Royal Bank of Canada	Set Price Target	Outperform	$188.00 ➝ $187.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
12/22/2016	Royal Bank of Canada	Lower Price Target	Outperform	$188.00 ➝ $187.00	N/A	i
12/20/2016	Credit Suisse Group	Set Price Target	Buy	$160.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
12/16/2016	Credit Suisse Group	Reiterated Rating	Outperform	$165.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
12/15/2016	SVB Leerink	Reiterated Rating	Outperform	$211.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
12/15/2016	Oppenheimer	Initiated Coverage	Market Perform		N/A	i
12/13/2016	Robert W. Baird	Reiterated Rating	Neutral	$145.00	N/A	i
12/13/2016	Wedbush	Reiterated Rating	Neutral	$135.00	N/A	i Rating by Heather Behanna at Wedbush
12/13/2016	Royal Bank of Canada	Reiterated Rating	Overweight		N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
12/13/2016	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		N/A	i
12/12/2016	Piper Jaffray Companies	Set Price Target	Buy	$176.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
12/12/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
12/12/2016	Royal Bank of Canada	Set Price Target	Buy	$188.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
12/12/2016	Jefferies Financial Group	Set Price Target	Hold	$120.00	N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
12/12/2016	Cowen	Reiterated Rating	Buy	$180.00	N/A	i Rating by Eric Schmidt at Cowen Inc
12/7/2016	BMO Capital Markets	Reiterated Rating	Outperform	$171.00	N/A	i
12/6/2016	Robert W. Baird	Reiterated Rating	Neutral	$145.00	N/A	i Rating by Michael Ulz at Robert W. Baird
12/5/2016	Wedbush	Reiterated Rating	Neutral	$135.00	N/A	i Rating by Heather Behanna at Wedbush
11/30/2016	SVB Leerink	Reiterated Rating	Outperform	$211.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
11/30/2016	(FBRC)	Reiterated Rating	Market Perform	$130.00	N/A	i Rating by Christopher James at (FBRC)
11/29/2016	Barclays	Upgrade	Equal Weight ➝ Overweight	$150.00 ➝ $155.00	N/A	i
11/14/2016	(FBRC)	Reiterated Rating	Hold		N/A	i Rating by Christopher James at (FBRC)
11/14/2016	Piper Jaffray Companies	Set Price Target	Buy	$176.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
11/11/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A	i
11/10/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$158.00	N/A	i
11/10/2016	Wedbush	Reiterated Rating	Neutral	$135.00	N/A	i Rating by Heather Behanna at Wedbush
11/7/2016	SVB Leerink	Reiterated Rating	Buy	$211.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
11/7/2016	Credit Suisse Group	Reiterated Rating	Buy	$165.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
11/6/2016	Piper Jaffray Companies	Set Price Target	Buy	$176.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
11/3/2016	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$164.00	N/A	i
10/28/2016	Wedbush	Boost Price Target	Neutral	$132.00 ➝ $135.00	N/A	i
10/28/2016	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$158.00	N/A	i
10/28/2016	(FBRC)	Upgrade	Underperform ➝ Market Perform	$130.00	N/A	i Rating by Christopher James at (FBRC)
10/7/2016	(FBRC)	Reiterated Rating	Sell		N/A	i Rating by christopher james at (FBRC)
10/4/2016	Brean Capital	Initiated Coverage	Buy	$221.00	N/A	i Rating by Jonathan Aschoff at Brean Capital
9/26/2016	SVB Leerink	Boost Price Target	Outperform	$210.00 ➝ $211.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
9/23/2016	Jefferies Financial Group	Lower Price Target	Hold	$140.00 ➝ $120.00	N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
9/22/2016	Wedbush	Initiated Coverage	Neutral	$132.00	N/A	i
9/22/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
9/20/2016	Citigroup	Boost Price Target	Buy	$154.00 ➝ $155.00	N/A	i Rating by Robyn Karnauskas at Citigroup Inc.
9/15/2016	(FBRC)	Initiated Coverage	Underperform		N/A	i
8/16/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$185.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
8/9/2016	Jefferies Financial Group	Reiterated Rating	Hold		N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
7/29/2016	Brean Capital	Reiterated Rating	Buy	$221.00	N/A	i Rating by Jonathan Aschoff at Brean Capital
7/29/2016	Barclays	Lower Price Target	Equal Weight	$165.00 ➝ $150.00	N/A	i
7/29/2016	Stifel Nicolaus	Lower Price Target	Buy	$195.00 ➝ $182.00	N/A	i
7/25/2016	Jefferies Financial Group	Reiterated Rating	Hold	$159.00 ➝ $140.00	N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
7/17/2016	SVB Leerink	Reiterated Rating	Buy	$200.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
7/13/2016	SunTrust Banks	Lower Price Target	Buy	$220.00 ➝ $197.00	N/A	i
7/12/2016	Royal Bank of Canada	Initiated Coverage	Outperform	$188.00	N/A	i
7/11/2016	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$186.00 ➝ $165.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
7/9/2016	Credit Suisse Group	Upgrade	Neutral ➝ Outperform		N/A	i Rating by Alethia Young at Credit Suisse Group AG
7/8/2016	SVB Leerink	Reiterated Rating	Buy	$200.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
7/7/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
6/29/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Sharon Stein at Cowen Inc
6/29/2016	Morgan Stanley	Reiterated Rating	Overweight		N/A	i Rating by Matthew Harrison at Morgan Stanley
6/27/2016	Citigroup	Upgrade	Neutral ➝ Buy	$154.00	N/A	i Rating by Robyn Karnauskas at Citigroup Inc.
6/26/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
6/17/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Geoff Porges at SVB Leerink LLC
6/13/2016	Robert W. Baird	Reiterated Rating	Neutral	$145.00	N/A	i Rating by Brian Skorney at Robert W. Baird
6/8/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
6/7/2016	Barclays	Lower Price Target	Equal Weight	$180.00 ➝ $165.00	N/A	i
6/7/2016	Citigroup	Reiterated Rating	Hold		N/A	i Rating by Robyn Karnauskas at Citigroup Inc.
6/7/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Geoff Porges at SVB Leerink LLC
6/7/2016	Oppenheimer	Reiterated Rating	Buy	$228.00 ➝ $221.00	N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.
6/7/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Jonathan Aschoff at Brean Capital
6/7/2016	BMO Capital Markets	Reiterated Rating	Buy	$168.00 ➝ $160.00	N/A	i Rating by Ian Somaiya at BMO Capital Markets
6/7/2016	Morgan Stanley	Reiterated Rating	Overweight	$203.00 ➝ $189.00	N/A	i Rating by Matthew Harrison at Morgan Stanley
6/6/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$212.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
6/6/2016	Credit Suisse Group	Reiterated Rating	Hold	$195.00 ➝ $186.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
6/6/2016	Bank of America	Reiterated Rating	Buy		N/A	i Rating by Ying Huang at Bank of America Co.
5/31/2016	Oppenheimer	Reiterated Rating	Outperform	$228.00	N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.
5/29/2016	Jefferies Financial Group	Reiterated Rating	Hold		N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
5/12/2016	SVB Leerink	Reiterated Rating	Buy	$200.00 ➝ $210.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
5/9/2016	Barclays	Boost Price Target	Equal Weight	$175.00 ➝ $180.00	N/A	i
4/30/2016	Morgan Stanley	Reiterated Rating	Buy		N/A	i Rating by Matthew Harrison at Morgan Stanley
4/30/2016	BMO Capital Markets	Downgrade	Buy		N/A	i Rating by Ian Somaiya at BMO Capital Markets
4/30/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Geoff Porges at SVB Leerink LLC
4/29/2016	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$165.00 ➝ $168.00	N/A	i
4/28/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
4/28/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Jonathan Aschoff at Brean Capital
4/28/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
4/26/2016	Oppenheimer	Reiterated Rating	Outperform	$228.00	N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.
4/17/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
4/10/2016	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by Geoff Porges at SVB Leerink LLC
4/8/2016	Morgan Stanley	Boost Price Target		$195.00 ➝ $210.00	N/A	i Rating by Matthew Harrison at Morgan Stanley
4/6/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$165.00	N/A	i
4/5/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$212.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
4/1/2016	Morgan Stanley	Reiterated Rating	Buy	$195.00	N/A	i Rating by Matthew Harrison at Morgan Stanley
3/19/2016	SVB Leerink	Reiterated Rating	Buy	$217.00 ➝ $216.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
3/7/2016	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$221.00 ➝ $170.00	N/A	i
3/7/2016	Cowen	Reiterated Rating	Buy	$216.00	N/A	i
2/25/2016	Citigroup	Initiated Coverage	Neutral	$165.00	N/A	i
2/22/2016	The Goldman Sachs Group	Lower Price Target		$186.00 ➝ $168.00	N/A	i
2/8/2016	Jefferies Financial Group	Reiterated Rating	Hold	$190.00 ➝ $165.00	N/A	i
2/6/2016	SVB Leerink	Reiterated Rating	Outperform	$217.00	N/A	i Rating by H. Liang at SVB Leerink LLC
2/5/2016	Bank of America	Reiterated Rating	Buy	$227.00 ➝ $204.00	N/A	i
2/4/2016	Stifel Nicolaus	Lower Price Target	Buy	$245.00 ➝ $230.00	N/A	i Rating by Stephen Willey at Stifel Nicolaus
2/4/2016	JPMorgan Chase & Co.	Lower Price Target		$225.00 ➝ $185.00	N/A	i
2/4/2016	Jefferies Financial Group	Lower Price Target	Hold	$190.00 ➝ $165.00	N/A	i
2/4/2016	The Goldman Sachs Group	Lower Price Target	Neutral	$199.00 ➝ $186.00	N/A	i
2/4/2016	UBS Group	Lower Price Target	Buy	$222.00 ➝ $200.00	N/A	i
2/4/2016	Brean Capital	Reiterated Rating	Buy	$221.00	N/A	i Rating by Jonathan Aschoff at Brean Capital
2/4/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$212.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
2/4/2016	Barclays	Lower Price Target	Equal Weight	$202.00 ➝ $175.00	N/A	i

(Data available from 1/20/2016 forward)

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $157.74

$157.26

$159.10

50 Day Range

MA: $147.47

$117.74

$158.71

52 Week Range

Now: $157.74

$72.67

$160.03

Volume

3,540,569 shs

Average Volume

3,364,677 shs

Market Capitalization

$34.52 billion

P/E Ratio

36.86

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Alexion Pharmaceuticals?

The following Wall Street research analysts have issued reports on Alexion Pharmaceuticals in the last twelve months: Bank of America Co., BMO Capital Markets, Cantor Fitzgerald, Cfra, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Nomura, Nomura Securities, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Roth Capital, Royal Bank of Canada, Sanford C. Bernstein, Smith Barney Citigroup, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, TheStreet, Truist, UBS Group AG, Wedbush, William Blair, Wolfe Research, and Zacks Investment Research.

What is the current price target for Alexion Pharmaceuticals?

26 Wall Street analysts have set twelve-month price targets for Alexion Pharmaceuticals in the last year. Their average twelve-month price target is $152.96, suggesting a possible downside of 3.6%. SVB Leerink LLC has the highest price target set, predicting ALXN will reach $200.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $73.00 for Alexion Pharmaceuticals in the next year.

What is the current consensus analyst rating for Alexion Pharmaceuticals?

Alexion Pharmaceuticals currently has 16 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALXN, but not buy more shares or sell existing shares.

What other companies compete with Alexion Pharmaceuticals?

Other companies that are similar to Alexion Pharmaceuticals include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Seagen, Exact Sciences, Incyte, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Repligen, Neurocrine Biosciences, Ionis Pharmaceuticals, Novavax and United Therapeutics.

How do I contact Alexion Pharmaceuticals' investor relations team?

Alexion Pharmaceuticals' physical mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company's listed phone number is 475-230-2596 and its investor relations email address is investorrelations@alexion.com. The official website for Alexion Pharmaceuticals is www.alexion.com.

NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for ALXN

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Alexion Pharmaceuticals?

What is the current price target for Alexion Pharmaceuticals?

What is the current consensus analyst rating for Alexion Pharmaceuticals?

What other companies compete with Alexion Pharmaceuticals?

How do I contact Alexion Pharmaceuticals' investor relations team?